SCHEMBL20488236

SCHEMBL20488236

CCOC(=O)c1[nH]nc(C)c1Cc1ccc(S(=O)(=O)N(C)C)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
MAPK1 P28482 1/20 0.38
TP53 P04637 1/20 0.37
THRB P10828 1/20 0.37
HPGD P15428 2/20 0.37
ALOX15 P16050 1/20 0.37
AR P10275 1/20 0.37
ALDH1A1 P00352 5/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 3/20 0.36
TSHR P16473 1/20 0.36
P2RX7 Q99572 1/20 0.36
MEN1 O00255 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
NPC1 O15118 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20489232 0.84 ALDH1A1 (0.45) MAPTTP53THRBHPGDALOX15
SCHEMBL21791586 0.82 GSTO1 (0.40) MAPTMAPK1ARALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL20489231 0.81 GSTO1 (0.40) MAPTMAPK1ARALDH1A1SMN1; SMN2
SCHEMBL20489107 0.81 MAPT (0.34) MAPTMAPK1ARALDH1A1SMN1; SMN2
SCHEMBL21773566 0.78 GSTO1 (0.38) MAPTARALDH1A1SMN1; SMN2LMNA
SCHEMBL7828097 0.78 LMNA (0.50) MAPTTP53HPGDALOX15AR
SCHEMBL20488878 0.77 GSTO1 (0.39) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL21791594 0.76 MAPT (0.45) MAPTMAPK1TP53THRBHPGD
SCHEMBL8188646 0.75 AR (0.51) MAPTHPGDALOX15ARALDH1A1
SCHEMBL6418611 0.73 AR (0.49) MAPTTP53HPGDALOX15AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2020-03-05 US disclosed
WO-2018157190-A9 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2018-10-25 WO disclosed
WO-2018157190-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200069648-A1 HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF LOX, DAO, AADAC MAPT 3516/4885MAPK1 2313/4885TP53 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.